Advances & Challenges in Immunotherapy in Head and Neck Cancer

Hazem Aboaid^1*Taimur Khalid²Abbas Hussain¹Yin Mon Myat³Rishi Kumar Nanda⁴Ramaditya Srinivasmurthy⁴Kevin Nguyen⁴Daniel Thomas Jones⁴Jo-Lawrence Bigcas⁵Kyaw Zin Thein⁶

• ¹Department of Internal Medicine, Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas, Las Vegas, Nevada, United States
• ²Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas, Las Vegas, Nevada, United States
• ³Department of Internal Medicine, One Brooklyn Health—Interfaith Medical Center Campus, Brooklyn, NY, United States
• ⁴Touro University Nevada College of Osteopathic Medicine, Las Vegas, NV, United States
• ⁵Department of Otolaryngology - Head & Neck Surgery, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, United States
• ⁶Division of Hematology and Medical Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV, United States

Head and neck squamous cell carcinoma (HNSCC) remains a challenging malignancy with suboptimal survival outcomes despite advances in surgery, radiotherapy, and chemotherapy. Immunotherapy, particularly immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1), has transformed treatment paradigms, yet its full potential in HNSCC is still being explored. This review evaluates the current landscape of immunotherapy in both locally advanced (LA) and recurrent/metastatic (R/M) HNSCC, discussing key clinical trials, emerging biomarkers, and novel therapeutic strategies.For LA HNSCC, phase III trials such as KEYNOTE-412 and JAVELIN Head and Neck 100 failed to demonstrate survival benefits with ICI-chemoradiotherapy combinations in unselected populations, though post hoc analyses suggest efficacy in PD-L1-positive tumors. Recent studies, including KEYNOTE-689 and NIVOPOSTOP GORTEC 2018-01, indicate potential benefits of perioperative ICIs in resectable disease.In R/M HNSCC, ICIs have redefined the standard of care. KEYNOTE-040 and CheckMate 141 led to Food and Drug Administration (FDA) approvals of pembrolizumab and nivolumab, while KEYNOTE-048 established pembrolizumab monotherapy for PD-L1 combined positive score (CPS) ≥1 and pembrolizumab plus chemotherapy as first-line treatment. However, dual checkpoint 1 blockade trials (KESTREL, CheckMate 651) have yielded mixed results, highlighting the complexity of immune resistance.Beyond ICIs, emerging strategies include oncolytic virotherapy, chimeric antigen receptor-T cell therapy (CAR-T), and cancer vaccines, with promising preclinical and early-phase clinical results. Biomarkers such as PD-L1 expression, tumor mutational burden (TMB), and Human Papillomavirus (HPV) status play a critical role in treatment selection, but further validation is needed.Despite advancements, challenges persist, including heterogeneous response rates, immune-related toxicities, and optimal integration of immunotherapy in multimodal treatment regimens. Future research should focus on refining biomarker-driven treatment algorithms, developing rational immunotherapy combinations, and leveraging tumor microenvironment modifications to enhance therapeutic efficacy.